Discover investment opportunities in Low Priced Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Low Priced Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Low Priced Biotech Stocks using our Smart AI Filter.
8 stocks found for "Low Priced Biotech Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.81 | ±48.4% | 14.1 | 0.00% | |||
1.01 | ±62.0% | 25.4 | 0.00% | |||
0.95 | ±90.4% | -0.8 | 0.00% | |||
1.34 | ±69.0% | -22.0 | 0.00% | |||
0.76 | ±41.4% | 25.6 | 0.00% | |||
2.17 | ±100.0% | -6.9 | 0.00% | |||
2.23 | ±99.6% | 441.5 | 0.00% | |||
0.86 | ±55.0% | 41.8 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What sector-specific opportunities do biotech stocks offer to investors?
A: Biotech stocks, such as SNDX and AUPH, can provide opportunities from groundbreaking drug developments and technological advancements. These companies often focus on innovative treatments and therapies, giving them the potential for high growth. However, they may also face challenges like regulatory hurdles and lengthy R&D cycles.
Q: Are there unique risks associated with investing in low-priced biotech stocks?
A: Investing in low-priced biotech stocks like LGVN and IGC can be risky due to market volatility, high dependency on successful clinical trials, and potential dilution from frequent fundraising. Additionally, regulatory changes and patent issues can impact their stock performance.
Q: How can biotech stocks like SNDX and AUPH perform during economic downturns?
A: Biotech stocks, including SNDX and AUPH, may display resilience during economic downturns if they offer essential drugs or treatments. However, reduced healthcare spending and increased competition can constrain their financial performance.
Q: Does investing in biotech stocks like CBIO offer potential for income through dividends?
A: Historically, biotech stocks such as CBIO generally do not offer dividends, prioritizing reinvestment in research and development. Investors seeking income should consider the company's long-term growth potential rather than immediate income.
Q: What competitive advantages might a biotech company like ANVS have?
A: Competencies like proprietary technology, strong R&D capabilities, and strategic partnerships can provide biotech companies like ANVS with competitive advantages. These factors may improve the company's innovation pipeline and financial stability.
Q: How does the geographic focus impact biotech stocks on the screener?
A: The specific geographic focus of biotech companies can influence factors such as regulatory environment, investor sentiment, and market access. Investors should consider where these companies, like PLRX, are based to assess regional opportunities and challenges.
The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read more